George Sledge, Jr., MD, discusses the overall survival data of the phase III MONARCH-2 trial in advanced hormone receptor-positive, HER2-negative breast cancer.
George Sledge, Jr., MD
Advertisement
Articles by George Sledge, Jr., MD
Advertisement
Latest Updated Articles
Overall Survival Data of the MONARCH-2 Trial in HR+/HER2- Breast CancerPublished: October 2nd 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
